209 results about "Plasma sample" patented technology

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

The invention discloses a colorectal cancer plasma circulating microbial marker, a reagent, a kit and application thereof, and belongs to the technical field of biomedical detection. The plasma circulating microbial marker for colorectal cancer comprises alternaria alternata, alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous alophilous The colorectal cancer plasma circulating microbial marker can be used for early screening of colorectal cancer, has relatively high sensitivity and specificity, and remarkably improves the accuracy and reliability of detection; the limitation of traditional ctDNA detection is broken through, and the detection rate of early colorectal cancer is improved. The colorectal cancer plasma circulating microbial marker in a colorectal cancer plasma sample is detected through low-depth whole genome sequencing, the requirement for depth in an experiment is reduced, the cost can be greatly reduced while high sensitivity and specificity are guaranteed, and the method is more suitable for large-scale screening.

The invention discloses a method for annotating a vesicle cell subset based on monovesicle membrane proteomics, and belongs to the technical field of vesicle cell annotation. The method comprises the following steps: 1, carrying out exosome collection on a plasma sample to obtain a sample; 2, coding and labeling the antibody probe, and adding a protein tag and a labeled DNA sequence into the antibody probe to obtain a labeled antibody probe; 3, preparing a corresponding combined product; 4, adding a labeled antibody probe into the sample to obtain an exosome compound; step 5, capturing an exosome conjugate through CTB; 6, adding the binding product into the exosome conjugate to generate a sequence; 7, constructing a sequence library and sequencing to obtain a sequencing sequence; 8, removing a sequencing sequence with low expression quantity to obtain an exosome expression data matrix, and standardizing the exosome expression data matrix; 9, carrying out clustering analysis to find out an exosome core subgroup; and step 10, determining the source of the exosome core subgroup, and annotating the single vesicle subgroup.

A method of pre-screening a human subject for a clinical trial for treatment of tauopathy or an amyloidogenic disease. The method comprises obtaining a plasma sample from the subject and determining a concentration of p217+tau present in the plasma sample. The method further comprises indicating the subject for further screening for the clinical trial when the concentration of p217+tau present in the plasma sample is greater than or equal to a minimum threshold and less than or equal to a maximum threshold. The minimum threshold corresponds to an amount of p217+tau in plasma over which subjects present with mild cognitive impairment (MCI) and an increased accumulation of tau tangles in the brain as compared to a cognitively normal patient. The maximum threshold corresponds to an amount of p217+tau present in plasma over which subjects present with pathology of widespread accumulation of tau tangles in multiple regions of the brain.

The invention relates to the field of medical informatics, and provides a diabetic nephropathy risk prediction method and system based on a protein marker. The method comprises the following steps: detecting the concentration of a protein marker in a plasma sample of a diabetic to obtain plasma protein marker concentration data; performing longitudinal correlation analysis on the protein markers according to the plasma protein marker concentration data to obtain the kidney disease related protein markers; performing feature screening on the kidney disease related protein marker combination to obtain a core protein marker; establishing a nephropathy risk prediction model through the clinical parameters of the diabetic patient and the core protein marker combination; and outputting a nephropathy risk prediction result of the patient to be detected through the nephropathy risk prediction model. The advanced intervention of the diabetic nephropathy is realized, and the prediction accuracy of the diabetic nephropathy is improved.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

本发明实施例公开了一种基于蛋白质组学的脓毒症休克患者液体管理策略预测方法。所述方法包括：收集脓毒症休克患者的血浆样本，检测蛋白质标志物的表达水平，所述蛋白质标志物为GAL、NFASC、MICB_MICA、MAP2K6、JCHAIN和CSF3的组合；基于亚组识别模型计算效益得分，获得脓毒症休克患者的液体管理策略结果。本发明通过收集脓毒症休克患者的临床数据和蛋白质表达数据，采用LASSO回归分析，构建基于上述蛋白质标志物的亚组识别模型，进而获得效益评分，基于效益评分能预测患者液体管理策略方案的适用性，为脓毒症休克患者的液体治疗提供了可靠的方案，实现个体化和精准的液体治疗，在临床具有较好的应用前景。

The application discloses a method for determining unbound concentration of lenvatinib, which comprises the following steps: sending standard curve working solution and quality control working solution into a liquid chromatography tandem mass spectrometry detection system to obtain a standard curve; adding a plasma sample into an ultrafiltration tube, centrifuging under the condition of a centrifugal force of 3000g for 15 min, and collecting an ultrafiltrate of the plasma sample; adding the ultrafiltrate of the plasma sample into blank plasma ultrafiltrate, mixing uniformly, taking supernatant into a collection plate, sending the collection plate into the liquid chromatography tandem mass spectrometry detection system to obtain a ratio of a peak area of lenvatinib to a peak area of an internal standard, and then bringing the area ratio into the standard curve to obtain the unbound concentration of lenvatinib in the plasma sample. The method for determining the unbound concentration of lenvatinib can accurately determine the unbound concentration of lenvatinib in plasma and overcome the prejudice of the prior art.

Systems, methods and computer-readable media are provided for identifying patients having an elevated near-term risk of chronic kidney disease (CKD) progression, including predicting an individual's risk of progression to Stage 3 CKD within a future time interval, which may be up to 36 months. Based on the prediction, appropriate care providers may be notified so that the risk of CKD progression may be mitigated. In an embodiment, measurements of physiological variables are obtained, including serial measurements for uric acid levels from a longitudinal time series of serum or plasma samples spanning the previous two to five years. An annualized uric acid velocity of the patient is determined and used to generate a multivariable mathematical model for determining a likelihood of risk for developing Stage 3 CKD within 36 months.

A system for determining a functional fibrinogen concentration from a patient's coagulating blood or blood plasma sample is configured to obtain a signal representing physical or biochemical properties of the developing fibrin network during coagulation of the patient's blood or blood plasma sample over time, determine the fibrinogen concentration based on one or more values of one or more features of the signal with the help of a learned function which maps values of the feature(s) to functional fibrinogen concentrations, and output the fibrinogen concentration, e.g. on a display. The feature(s) include(s) multiple of features related to 1) a maximum value of the gradient of the signal, 2) the maximum of the second derivative of the signal, 3) a difference between the maximum and the minimum of the signal, and 4) the minimum of the second derivative of the signal, or at least feature 1) or 2).

Despite the high prevalence and serious clinical implications of metabolic associated steatohepatitis (MASH) in patients with type 2 diabetes (T2D), MASH is usually overlooked in clinical practice, due to the lack of accurate biomarkers. The inventors evaluated the ability of plasma large extracellular vesicles (lEVs) to serve as noninvasive biomarkers for the diagnosis of MASH, in particular in T2D patients. Proteomic analysis identified Transferrinreceptor on lEVs (TFRC-lEVs) as associated with MASH. The inventors thus measured TFRC- lEVs on plasma samples from patients included in the derivation cohort. The proportion of patients with TFRC-lEVs concentration > 61 ng / mL was significantly higher in patients with MASH than in those with steatosis. TFRC-lEVs > 61 ng / mL remained associated with MASH after adjustment on either usual laboratory variables, or on the NASH-Test or on the Fibroscan FAST-score. When combining TFRC-lEVs with available methods the population suspected of having MASH was 32% and 29%, versus 22% and 16% for NASH-test or FAST score alone, without decreasing specificity. In conclusion, TFRC-lEVs, a marker of hepatocyte ballooning, is a promising biomarker for MASH. It could be used for patients' screening to enlarge recruitment of patients with MASH in clinical trials.

Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.

This invention relates to a method for detecting tRF-type gastric cancer molecular markers in plasma and their application in the preparation of a gastric cancer auxiliary diagnostic kit. The kit is characterized by including reagents for detecting tRF-18-79MP9P04, tRF-30-87R8WP9N1EWJ, tRF-21-V2989UV3B, and tRF-33-P4R8YP9LON4VDP in plasma samples. Compared with existing technologies, the advantages of this invention are: the kit combines tRF-18-79MP9P04, tRF-30-87R8WP9N1EWJ, tRF-21-V2989UV3B, and tRF-33-P4R8YP9LON4VDP as markers for the auxiliary diagnosis of early gastric cancer, enabling accurate absolute quantitative detection of target molecules and screening and identification of early gastric cancer.

The invention relates to oil seal liquid and application thereof in blood coagulation detection, and belongs to the technical field of blood coagulation detection. The oil seal liquid can form a uniform film when covering a plasma sample, the activity of thrombin is not affected while air is isolated, and in addition, the oil seal liquid is a biological inert formula, is easy to clean and does not generate adsorption or reaction with blood coagulation factors and reagents. Therefore, the oil seal liquid and the sample are incubated synchronously in the pre-warming stage, and errors caused by sample evaporation and temperature fluctuation in the pre-warming stage can be reduced. Compared with traditional paraffin oil, the oil seal liquid can effectively isolate air to avoid sample evaporation and reduce reagent interference, is easy to clean, provides reliable technical support for blood coagulation factor deficiency and precise identification of inhibitors, and is suitable for APTT correction experiments, PT correction experiments or clinical detection and application of lupus anticoagulant (LA).

Ovarian cancer risk in a female human subject is predicted by determining the amount of STK1 substance in a serum or plasma sample from the female human subject using first and second monoclonal antibodies or antigen-binding fragments thereof that specifically bind to the serum form of human TK1. The amount of CA 125 or HE4 is determined in the serum or plasma sample or another serum or plasma sample from the female human subject. The risk of ovarian cancer in the female human subject is then predicted based on the amount of STK1 substance and the amount of one but not both of CA 125 and HE4.

The application discloses a CKD and IgAN early detection method based on blood mass spectrum analysis, utilizes liquid chromatography-tandem mass spectrometry technology to detect 24 kinds of compounds of a plasma sample in a targeted manner, utilizes a logic regression to establish an early detection model of CKD and IgAN, and verifies the prediction accuracy of CKD and IgAN in a cohort. Through analysis of plasma samples of healthy controls and CKD patients (including IgAN and non-IgAN patients), it is proved that the melatonin or melatonin+tryptophan level in the plasma is an effective method for detecting early CKD, and the melatonin, tryptophan, indole-3-lactic acid, indole-3-carboxylic acid, kynurenic acid and indole-3-methyl aldehyde are effective methods for detecting early IgAN. The application provides effective blood markers for early detection of CKD and IgAN.

Disclosed is a method for diagnosing a cancer health status, or a change in cancer health status, or for diagnosing a risk of cancer change or presence in a patient, comprising determining in a plasma sample from the patient one or more biomarker values corresponding to a complex structure containing alpha-1 antitrypsin (A1AT), and based on the biomarker values, determining the patient as suffering or not suffering from cancer, or having or not having a change in cancer health status, or having or not having a risk of cancer, wherein the cancer is selected from the group consisting of hepatocellular carcinoma (HCC), ovarian cancer (OC), and breast cancer (BC).

The invention provides a method for simultaneously determining ritocaine and prilocaine in blood plasma based on a liquid chromatography-tandem mass spectrometry (LC-MSMS) technology. The specific operation of the method comprises the following steps: adding an internal standard solution and an organic solvent into a plasma sample, and ensuring full extraction of lidocaine and prilocaine through vortex mixing. And separating by using a centrifugal technology, and collecting supernate as a pretreated sample to be detected. An Eclipse Plus C18 chromatographic column is adopted for isocratic elution, effective separation of lidocaine and prilocaine is achieved, and then a sample is subjected to mass spectrometric detection. A standard curve is drawn based on the mass spectrum peak area ratio, a regression equation is obtained, and the concentration of lidocaine and prilocaine in the sample to be detected is obtained through calculation. The method has the characteristics of simplicity and convenience in pretreatment operation, low plasma consumption, short analysis time and high sensitivity, and is suitable for detection of lidocaine and prilocaine in plasma and clinical pharmacokinetic research of the lidocaine cream.

The invention provides a method for detecting polymyxin E in plasma based on combination of magnetic bead extraction and liquid chromatography-tandem mass spectrometry, and the method comprises the following steps: by taking polymyxin B1 as an internal standard, pretreating a plasma sample by adopting HLB magnetic beads; and quantifying the content of polymyxin E in the plasma by using liquid chromatography-tandem mass spectrometry. According to the application, the HLB magnetic beads are combined with an automatic treatment system, so that the balancing, extracting and washing steps are simplified, the time and the material cost are remarkably reduced, the pretreatment of the plasma sample is simple and rapid, and interfering substances are removed to the greatest extent; the method shows excellent selectivity and specificity, the average recovery rate is between 99.91 + / -5.45% and 103.1 + / -8.90%, the matrix effect can be ignored, the lowest limit of detection (LLOD) reaches 0.01 mu g / mL, the wide linear range of 0.01-20 mu g / mL is achieved, and a rapid solution is provided for clinical treatment drug monitoring of polymyxin E.

Disclosed herein are methods of immunoassay for detecting in a patient sample (such as for example a blood, serum or plasma sample) a biomarker (PRO-C12) originating from Type XII Collagen. Said methods may be used for detecting and / or monitoring cancer or a level of severity thereof. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.

A method of diagnosing Alzheimer's disease and related dementias (ADRD) in a patient comprising obtaining a plasma sample from the patient; determining a level of a biochemical sulfide in the plasma sample from the subject by trapping volatilized H2S in the plasma sample using alkaline buffer with monobromobiamine, and detecting the level of biochemical sulfide in the plasma sample, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide; and diagnosing the patient with ADRD when the level of the biochemical sulfide is at least an elevated threshold level for the biochemical sulfide.

Disclosed is a method for diagnosing a cancer health state, or a change in cancer health state in a patient, or for diagnosing a risk of the change or presence of a cancer in a patient, comprising determining, in a plasma sample from said patient, one or more biomarker values that correspond to transthyretin-containing complex structures, and assigning the patient as having or not having cancer, or having or not having a change in cancer health state, or having or not having a risk of cancer based on said biomarker values, wherein said cancer is preferably lung cancer (LC).

The present invention discloses a method for evaluating the chromatographic effect of a blood-separated plasma sample based on image detection. First, a high-resolution camera or a video camera is used to collect a blood separation image in real time, and a suitable light source is configured to eliminate errors caused by changes in the color or transparency of the blood. Furthermore, the collected image is preprocessed (such as grayscale processing) to convert the original blood stratification effect into a clear grayscale image. Furthermore, after the blood is centrifuged to form a red blood cell layer, a white blood cell-platelet layer, and a plasma layer, and then the top layer of the blood, i.e., the plasma layer, or an area containing a small portion of the white blood cell-platelet layer, is quickly located and extracted through coarse segmentation. Furthermore, through fine segmentation, the white blood cell-platelet layer is removed from the plasma layer to obtain an image with clear edges and containing only the plasma layer. Finally, an evaluation is performed based on the impurity content of the plasma layer in the image, and a purity analysis result is ultimately given.

The invention provides a pretreatment method for mass spectrometric detection of plasma protein and a kit. A plurality of plasma treatment means are combined by comprehensively applying acetonitrile; the serum specifically comprises 10% of whole plasma, 20% of acetonitrile precipitate, 10% of 40% acetonitrile precipitate, 20% of 50% acetonitrile supernatant, and 20% of supernatant obtained by removing albumin after precipitating the plasma with 10% and 20% of polyethylene glycol respectively. Deep proteomic analysis is carried out on the redistributed plasma sample, 5441 proteins are identified from 5336 genes, and proteins with the concentration as low as nanogram / upgrade are detected. On the premise that common abundance proteins are not removed, more than 5000 proteins are successfully identified under the conditions of about 100 non-tandem components and 2-hour gradient operation, and the maximum scale of mass spectrum-based plasma proteomics research is achieved.

The invention discloses an i-motif DNA (deoxyribonucleic acid) modified gold nano flare, a preparation method of the i-motif DNA modified gold nano flare and application of the i-motif DNA modified gold nano flare to detection of miRNA, and belongs to the technical field of nano biological materials and molecular diagnosis. The fluorescence probe is formed by assembling gold nanoparticles and an i-motif molecular fluorescence probe, the i-motif molecular fluorescent probe contains four sections of sequences rich in C basic groups and a target miRNA recognition chain, sulfydryl is marked at the 5'end, and fluorescent molecules are marked at the 3 'end. The probe is prepared by adopting a freeze thawing method, the labeling density of the probe is high, in a constructed detection system, the miR-21 detection limit is as low as 1.01 fM, and single-base mutants can be accurately distinguished; the technology does not need complex sample pretreatment and can be directly used for detecting cell total RNA or miRNA in a plasma sample, and the detection result is highly consistent with RT-qPCR; the problems of low marking efficiency and insufficient sensitivity in the prior art are effectively solved, and an innovative tool with high sensitivity, high specificity and clinical suitability is provided for tumor-associated miRNA molecular diagnosis.

The application provides a plasma exosome purification system, and belongs to the field of biomedical engineering. The system comprises: an affinity chromatography pretreatment module, which is used for specifically adsorbing exosomes from a plasma sample, and obtaining an exosome eluate through washing and elution; an ultrasonic nanofiltration module, which is used for filtering the exosome eluate under the action of ultrasonic waves to retain the exosomes and remove small molecular impurities, and obtaining an exosome concentrate; a pipetting module, which is used for performing liquid transfer operations of the plasma sample, the washing liquid, the eluate and the exosome eluate among the modules; and a main control module, which is in communication connection with the pipetting module and is used for controlling the pipetting module to perform the liquid transfer operations. The application combines the affinity chromatography and ultrasonic nanofiltration purification technologies, and realizes automatic pipetting control with the help of the main control module and the pipetting module, thereby significantly improving the purity of separation and purification while ensuring the integrity of the exosomes.

1. The name of the design product: fluorescent immunoassay analyzer (RealG-FL12 Pro). 2. The use of the design product: a medical testing device for detecting the analyte in human whole blood, serum and plasma samples, etc., using fluorescent immunoassay technology to excite and measure the fluorescent signal, thereby realizing rapid identification and quantitative analysis of pathogens, and providing important information for the diagnosis and treatment of infectious diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The utility model relates to the technical field of biological medicine, and discloses a plasma sample derivatization treatment device which comprises a treatment tank, an extension sleeve disc is fixedly connected to the outer surface of the treatment tank, a supporting block is jacked through a hydraulic rod, a connecting shaft and a fishing disc are driven to move upwards from the bottom of the treatment tank, and the treatment tank is driven to rotate. When the fishing disc reaches the position where the adsorption pipe is located, due to the fact that the notch groove in the surface of the fishing disc is matched with the adsorption pipe and the notch groove and the adsorption pipe are combined, the air pump is started, and the air pump adsorbs the non-polar biological matrix in the fishing disc through the adsorption pipe; then the adsorbed non-polar biological matrix is conveyed into the impurity box, so that the problems of incomplete cleaning, low efficiency and the like possibly existing in a traditional manual cleaning mode are avoided, and meanwhile, the adverse effect on subsequent detection work caused by matrix residues is also effectively avoided; and the conditions of inaccurate detection result, damage to detection equipment and the like which are possibly caused by matrix residue are solved.